Atossa Genetics is a clinical-stage pharmaceutical company focused on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company's leading program uses its patented intraductal microcatheters that deliver pharmaceuticals through the breast milk ducts. Atossa has initiated a Phase 2 clinical study using its microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ and breast cancer.
Oral endoxifen is the Company's second development program. Endoxifen is an active metabolite of tamoxifen, an FDA approved drug for breast cancer patients to prevent recurrence as well as new breast cancer.
Atossa Genetics is passionate about improving breast health and the overall well-being and health of women and men.
Net income (FY, 2017)
EBIT (FY, 2017)
Market capitalization (14-Jun-2018)
Closing share price (14-Jun-2018)